FDA Approves SOTYKTU — E.R. Squibb & Sons, L.L.C.

The FDA has granted approval to Squibb’s oral drug SOTYKTU (deucravacitinib) for the treatment of moderate-to-severe plaque psoriasis, a development that may allow the pharmaceutical giant to accelerate its entry into the highly competitive biologic segment while diversifying its revenue streams beyond the oncology niche.